<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04424420</url>
  </required_header>
  <id_info>
    <org_study_id>2018-004187-60</org_study_id>
    <nct_id>NCT04424420</nct_id>
  </id_info>
  <brief_title>Mental Effects of Analgesic Drugs: Paracetamol and Ibuprofen</brief_title>
  <acronym>MEAD</acronym>
  <official_title>Double Blinded Randomized Placebo Controlled Study on Mental Effects of Analgesic Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Jürgen Brockmöller</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Göttingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present study is to study paracetamol effects on social pain and empathy
      under standardized international conditions (ICH-GCP) for planning, conduction and reporting
      of clinical pharmaceutical studies in humans. The study included MRI imaging of brain
      activity, analysis of genomic biomarkers potentially explaining interindividual variation. It
      is controversial whether the effects are of immediate nature or develop during a period of
      about 10 days. Therefore, the study is separated into two study phases. Single dosing (SD) is
      applied in study phase 1 and multiple-dosing (MD) in study phase 2. The study compares
      paracetamol with placebo and in the study phase 1 also with ibuprofen as analgetically active
      control.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective with placebo-controlled</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of paracetamol and ibuprofen on social pain and empathy</measure>
    <time_frame>8 hours</time_frame>
    <description>Primary outcome is defined as the composite score of standardized emotional scenarios and the hurt feeling scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of paracetamol on social pain and empathy</measure>
    <time_frame>14 days</time_frame>
    <description>Primary outcome is defined as the composite score of standardized emotional scenarios and the hurt feeling scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychological effects of paracetamol and ibuprofen</measure>
    <time_frame>8 hours</time_frame>
    <description>Interindividual variation of analgesic effects measured using fMRI. MRI will be performed to reflect differences in brain activation by Psychometric test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics effects of paracetamol and ibuprofen</measure>
    <time_frame>8 hours</time_frame>
    <description>Blood samples for determination of study drug concentrations in plasma will be taken at different time-point. This will be used to calculate Maximum Plasma Concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenes roles in paracetamol and ibuprofen metabolism</measure>
    <time_frame>8 hours</time_frame>
    <description>Genetic analysis of relevant genes responsible for paracetamol and ibuprofen Absorption, Distribution, Metabolism and Excretion (ADME).Healthy volunteers will provide a blood sample for molecular genetic analyses of the various candidate genes, e.g. drug transporters and metabolizing enzymes. This will shed light on the interindividual variation of analgesic effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological effects of paracetamol</measure>
    <time_frame>14 days</time_frame>
    <description>Interindividual variation of analgesic effects measured using fMRI. MRI will be performed to reflect differences in brain activation by Psychometric test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics effects of paracetamol</measure>
    <time_frame>14 days</time_frame>
    <description>Blood samples for determination of study drug concentrations in plasma will be taken at different time-point. This will be used to calculate Maximum Plasma Concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenes roles in paracetamol metabolism</measure>
    <time_frame>14 days</time_frame>
    <description>Genetic analysis of relevant genes responsible for paracetamol Absorption, Distribution, Metabolism and Excretion (ADME). Healthy volunteers will provide a blood sample for molecular genetic analyses of the various candidate genes, e.g. drug transporters and metabolizing enzymes. This will shed light on the interindividual variation of analgesic effects.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Empathy</condition>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study phase 1 (single dosing): 1000 mg once. Study phase 2 (multiple dosing): 1000 mg twice daily for a minimum of 12 and a maximum of 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study phase 1 (single dosing): 800 mg once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study phase 1 (single dosing): Once. Study phase 2 (multiple dosing): Twice daily for a minimum of 12 and a maximum of 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Paracetamol oral tablet</description>
    <arm_group_label>Paracetamol</arm_group_label>
    <other_name>Acetaminophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen oral tablet</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Sugar pill manufactured to mimic the Paracetamol and Ibuprofen.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent obtained prior to study.

          2. Willingness to meet the study instructions and to co-operate with the study personal.

          3. No clinically relevant pathological findings in any of the investigations at the
             screening visit; minor deviations of laboratory values from the normal range may be
             accepted if judged by the investigator to have no clinical relevance.

          4. Body weight not less than 48 kg and body mass index (BMI) not less than 17 kg/m² and
             not greater than 32 kg/m².

        Exclusion Criteria:

          1. Pacemaker devices, implantable or external ones.

          2. Involvement in the planning and conduct of the study (applies to staff directly
             employed at the study site / department).

          3. Known pregnancy or lactation period.

          4. History of alcohol and / or drug abuse and / or any abusive use of medicaments.

          5. Any disease affecting liver or kidney or impairment of the liver or kidney-function.

          6. History of severe hypersensitivity reactions, anaphylaxis, psychiatric or neurologic
             disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jürgen Brockmöller, Prof.</last_name>
    <phone>+49 (0) 551 39-53 11</phone>
    <email>jbrockm@gwdg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johannes Matthaei, Dr.med.</last_name>
    <email>matthaei.j@googlemail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Brockmöller, Prof.</last_name>
      <phone>+49(0)551 39 5311</phone>
      <email>jbrockm@gwdg.de</email>
    </contact>
    <contact_backup>
      <last_name>Alexandra Sachkova</last_name>
      <phone>+4917627786662</phone>
      <email>alexandra.sachkova@med.uni-goettingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Göttingen</investigator_affiliation>
    <investigator_full_name>Prof. Jürgen Brockmöller</investigator_full_name>
    <investigator_title>Director, Institute of Clinical Pharmacology at Universitätsmedizin Göttingen</investigator_title>
  </responsible_party>
  <keyword>Mental effects</keyword>
  <keyword>Social Pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

